Sponsored Lunch and Learn Presentation*
12:30PM – 2:00 PM | Saturday, September 18, 2021
Speaker: Shintaro Ichikawa, Ph.D
Pre- and probiotics have become mainstream solutions for improved overall wellbeing, but research has revealed that paraprobiotics, heat-killed probiotic strains, can also have very specific benefits and an influence on the immune system and overall immune health. Paraprobiotics also deliver the added advantage of a longer shelf-life without the need for refrigeration.
Shintaro Ichikawa, Ph.D., will discuss how paraprobiotics will benefit patients, the importance of paraprobiotics for immune health and introduce you to IMMUSE™ and EYEMUSE™, innovative branded forms of clinically studied strains that help to bolster immune function and vision health by stimulating immune cells within the gut and the retina. IMMUSE is currently supported by 11 human trials and EYEMUSE is supported by two.
- Attain an understanding of the immune system and the role of it in overall health.
- Understand Paraprobiotics and the difference between pre & pro biotics.
- Learn about the clinically published research behind the unique paraprobiotic strains used for IMMUSE™ and EYEMUSE™.
About The Speaker:
Dr. Shintaro Ichikawa is the Director of Technical Affairs at Kyowa Hakko USA, leading the launch of the company’s unique Lactococcus lactis strain plasma, IMMUSE™, in the United States. Dr. Ichikawa led the launch of IMMUSE™ in Japan previously. Dr. Ichikawa received his doctorate in life science from the University of Tokyo, Department of applied biochemistry. Prior to joining Kyowa Hakko USA in 2019, Dr. Ichikawa served as the Manager of Corporate Strategy and Principal Investigator for Kirin Holdings, where he was responsible for the company’s research and development laboratory for over ten years. Having studied at the La Jolla Institute for Immunology at the University of San Diego as a visiting scientist, Dr. Ichikawa developed a keen interest and expertise in the immune health sector with a particular emphasis on delivering benefits via innovative delivery formats and based on the microbiome.
*Denotes a Non-CME activity.